Pfizer Inc. (NYSE:PFE) Stake Lessened by Secure Asset Management LLC

Secure Asset Management LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 63.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,501 shares of the biopharmaceutical company's stock after selling 55,373 shares during the quarter. Secure Asset Management LLC's holdings in Pfizer were worth $824,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Long Run Wealth Advisors LLC increased its holdings in shares of Pfizer by 12.0% in the 1st quarter. Long Run Wealth Advisors LLC now owns 58,236 shares of the biopharmaceutical company's stock worth $1,476,000 after acquiring an additional 6,235 shares during the period. Teamwork Financial Advisors LLC increased its stake in shares of Pfizer by 10.3% in the first quarter. Teamwork Financial Advisors LLC now owns 50,040 shares of the biopharmaceutical company's stock valued at $1,268,000 after purchasing an additional 4,653 shares during the period. Greenfield Savings Bank raised its holdings in shares of Pfizer by 4.0% during the first quarter. Greenfield Savings Bank now owns 37,333 shares of the biopharmaceutical company's stock valued at $946,000 after buying an additional 1,451 shares during the last quarter. Apella Capital LLC boosted its position in shares of Pfizer by 6.5% during the first quarter. Apella Capital LLC now owns 22,602 shares of the biopharmaceutical company's stock worth $573,000 after buying an additional 1,374 shares during the period. Finally, Silverberg Bernstein Capital Management LLC grew its holdings in Pfizer by 19.5% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 9,800 shares of the biopharmaceutical company's stock worth $248,000 after buying an additional 1,600 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Pfizer stock traded up $0.24 during mid-day trading on Friday, hitting $23.36. The company's stock had a trading volume of 30,404,818 shares, compared to its average volume of 40,940,202. The stock has a market capitalization of $132.81 billion, a P/E ratio of 16.57, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock's fifty day moving average price is $22.97 and its two-hundred day moving average price is $25.01. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.82 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.36%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on PFE. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. UBS Group lifted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.